Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Filter

Your Filters

Publisher : mre press

Reset filters

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Efficacy and safety of bevacizumab in the treatment of advanced or recurrent cervical cancer: a systematic review and a meta-analysis.

Authors : Simin Xiao¹; Yang Xu²; Siyuan Zeng^3,4

Source: European Journal of Gynaecological Oncology. Aug2025, Vol. 46 Issue 8, p1-10. 10p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Combined pembrolizumab and bevacizumab therapy in heavily treated recurrent ovarian cancer.

Authors : Shin-Yi Wang¹; Yu-Ting Chou¹; Kuo-Chang Wen^1,2

Source: European Journal of Gynaecological Oncology. Aug2025, Vol. 46 Issue 8, p48-57. 10p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

Authors : Ghezelayagh, Talayeh S.¹ ; Wu, Emily S.^1,2; Barber, Emma L.³

Source: European Journal of Gynaecological Oncology. Feb2023, Vol. 44 Issue 1, p17-25. 9p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The effect of bevacizumab maintenance therapy on survival in recurrent epithelial ovarian cancer.

Authors : Bakır, Mehmet Sait¹ ; Birge, Özer¹; Karadag, Ceyda¹

Source: European Journal of Gynaecological Oncology. 2021, Vol. 42 Issue 6, p1198-1204. 7p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Real-world bevacizumab utilization and outcomes among women with ovarian cancer in Europe and the United States.

Authors : Monberg, Matthew J.¹ ; Hall, Jennifer P.²; Moon, Rebecca²

Source: European Journal of Gynaecological Oncology. 2021, Vol. 42 Issue 6, p1252-1261. 10p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse.

Authors : Kose, Fatih¹ ; Alemdaroğlu, Songül²; Mertsoylu, Hüseyin¹

Source: European Journal of Gynaecological Oncology. 2020, Vol. 41 Issue 6, p989-995. 7p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer.

Authors : Heesterbeek, C. J.^1,2 ; Thijs, A. M.¹; Hermans, R. H. M.³

Source: European Journal of Gynaecological Oncology. 2020, Vol. 41 Issue 3, p364-367. 4p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Salvage chemotherapy and maintenance therapy with poly adenosine diphosphate-ribose polymerase inhibitors for bevacizumab-resistant relapse of epithelial ovarian cancer.

Authors : Takuya Yokoe¹ ; Masato Kita¹; Yusuke Butsuhara¹

Source: European Journal of Gynaecological Oncology. Oct2022, Vol. 43 Issue 5, p24-31. 8p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution.

Authors : Chay, W. Y.^1,2 ; Kumar, A.³; Hoskins, P. J.¹

Source: European Journal of Gynaecological Oncology. 2018, Vol. 39 Issue 6, p877-880. 4p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report.

Authors : Takuya Yokoe¹ ; Masato Kita¹; Gen-ichiro Sumi¹

Source: European Journal of Gynaecological Oncology. Jun2022, Vol. 43 Issue 3, p147-151. 5p.

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Efficacy and safety of bevacizumab in the treatment of advanced or recurrent cervical cancer: a systematic review and a meta-analysis.

Combined pembrolizumab and bevacizumab therapy in heavily treated recurrent ovarian cancer.

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

The effect of bevacizumab maintenance therapy on survival in recurrent epithelial ovarian cancer.

Real-world bevacizumab utilization and outcomes among women with ovarian cancer in Europe and the United States.

Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse.

Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer.

Salvage chemotherapy and maintenance therapy with poly adenosine diphosphate-ribose polymerase inhibitors for bevacizumab-resistant relapse of epithelial ovarian cancer.

Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution.

Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report.

Contact

Follow us